Melbourne, Australia · Founded 2020 · Privately Held (backing)
Developer of CAR-T cell therapies designed to treat solid cancers. Currus Biologics is based in Melbourne, Australia and was founded in 2020. Its last reported valuation was $21.6 million in Oct 2025. It has raised $19.3 million.
Last reported valuation
$21.6M
Oct 2026
Priced at
—
Total raised
$19.3M
Last round
—
Cap table — not yet on record
Currus Biologics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Currus Biologics with a free account
·Watch Currus Biologics: the Monday email on marks, rounds and moves
